PharmaEssentia Corp (藥華醫藥) yesterday said it had gained approval from the Food and Drug Administration to proceed with a phase III global clinical trial to add hepatitis B as an indication for ropeginterferon alfa-2b, its newly approved polycythemia vera (PV) drug.
The company is planning to enroll 212 e-antigen positive hepatitis B patients worldwide and complete the phase III trial over the next two to three years, it said.
The announcement came after the European Medicines Agency earlier this week gave marketing authorization for the PV drug in the eurozone.
The parameters of the clinical trial leverages biomarkers to identify patients who are more likely to respond to the company’s interferon drug, PharmaEssentia chief executive Lin Ko-chung (林國鐘) said.
Hepatitis B is a highly contagious disease with more than 400 million chronic carriers worldwide and it leads to 1 million deaths a year, the company said.
There are between 10 million and 30 million new cases each year, and between 5 and 10 percent are likely to be hereditary carriers that do not show symptoms of the disease due to their genetic traits.
Studies show that 30 percent of the hereditary carriers with high concentrations of hepatitis B core antigen are likely to respond well to interferon treatments, the company said, noting that its phase III trial is targeting those patients.
Chronic infections such as hepatitis B are currently treated with nucleoside analogs or long-acting interferons such as Roche Holding AG’s Pegasys, but each has its shortcomings.
Nucleoside analogs have high toxicity profiles and only suppress the disease, while Pegasys has limited effectiveness and requires frequent injections.
Phase I and II trials showed that compared with Pegasys, PharmaEssentia’s interferon produced shorter seroconversion periods — the time it takes for patients to develop antibodies against e-antigen that can be detected in blood tests — among select patients, it said.
The interferon requires only biweekly injections and has milder side effects, and could be an option to meet currently unmet medical needs, the company said.
The company said it is working on the phase III trial with Linkou Chang Gung Memorial Hospital and Keelung Chang Gung Memorial Hospital.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last